

# Immunity induced by Yellow Fever vaccination in the elderly (60 years or OLDer) traveller

<b>Submission date</b> 05/09/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 05/09/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/10/2021	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr A.H.E. Roukens

**Contact details**  
Leiden University Medical Centre (LUMC)  
PO Box 9600  
Leiden  
Netherlands  
2300 RC  
-  
a.h.e.roukens@lumc.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
LUMC

# Study information

## Scientific Title

Immunity induced by Yellow Fever vaccination in the elderly (60 years or OLDer) traveller

## Acronym

YFOLD

## Study objectives

The induction of immunity might be slower in older persons than in younger individuals. This could influence the occurrence of adverse events induced by the vaccine.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Multicentre randomized active-controlled parallel-group trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Prevention

## Participant information sheet

## Health condition(s) or problem(s) studied

Yellow Fever vaccination

## Interventions

Yellow fever vaccination (only an extra intervention in control group), blood drawing and urine sampling.

## Intervention Type

Biological/Vaccine

## Phase

Not Applicable

## Primary outcome measure

1. Neutralizing antibodies
2. Yellow fever viremia

**Secondary outcome measures**

1. Presence of yellow fever virus proteins in urine samples
2. Adverse events

**Overall study start date**

01/10/2007

**Completion date**

01/10/2008

**Eligibility****Key inclusion criteria**

Elderly group:

1. Age of 60 years or older
2. Indication for yellow fever vaccination according to Dutch travel guidelines

Control group: age under 60 years

**Participant type(s)**

Patient

**Age group**

Mixed

**Sex**

Both

**Target number of participants**

60

**Total final enrolment**

58

**Key exclusion criteria**

1. Immune suppression due to disease or medication
2. Pregnancy

**Date of first enrolment**

01/10/2007

**Date of final enrolment**

01/10/2008

**Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

**Leiden University Medical Centre (LUMC)**

Leiden

Netherlands

2300 RC

## **Sponsor information**

**Organisation**

Leiden University Medical Centre (LUMC) (The Netherlands)

**Sponsor details**

Department of Infectious Diseases

P.O. Box 9600

Leiden

Netherlands

2300 RC

+31 (0)71 526 9111

a.h.e.roukens@lumc.nl

**Sponsor type**

Hospital/treatment centre

**Website**

[http://www.lumc.nl/english/start\\_english.html](http://www.lumc.nl/english/start_english.html)

**ROR**

<https://ror.org/027bh9e22>

## **Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

Leiden University Medical Centre (LUMC) (The Netherlands)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		07/12/2011	07/10/2021	Yes	No